Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hANP for prevention of acute kidney injury after infant cardiac surgery
2025-524069-26-00Phase 2Authorised
- Sponsor
- Region Västra Götaland
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carperitide in acute kidney failure (AKF) (3 arms), sponsored by Region Västra Götaland. Primary endpoint: Change in measured creatinine clearance from baseline to 5 hours after infusion start. Planned start May 2026; status: authorised.
02
Drugs
carperitide
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on 2025-524069-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524069-26-00.